BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9777982)

  • 1. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1203-14. PubMed ID: 9777982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas.
    Khoury N; Raju U; Crissman JD; Zarbo RJ; Greenawald KA
    Hum Pathol; 1990 Aug; 21(8):811-9. PubMed ID: 1696923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
    Takeshima Y; Amatya VJ; Kushitani K; Inai K
    Am J Clin Pathol; 2008 Nov; 130(5):771-9. PubMed ID: 18854270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
    Ordóñez NG
    Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
    Koutselini HA; Lazaris AC; Thomopoulou G; Papayannopoulou A; Kairi-Vasilatou E
    Adv Clin Path; 2001 Jul; 5(3):99-104. PubMed ID: 11753882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful.
    Barnetson RJ; Burnett RA; Downie I; Harper CM; Roberts F
    Am J Clin Pathol; 2006 Jan; 125(1):67-76. PubMed ID: 16482993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update.
    Ordóñez NG
    Adv Anat Pathol; 2006 Jan; 13(1):16-25. PubMed ID: 16462153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential diagnosis of primary peritoneal papillary tumors.
    Gitsch G; Tabery U; Feigl W; Breitenecker G
    Arch Gynecol Obstet; 1992; 251(3):139-44. PubMed ID: 1376598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
    Pisharodi LR; Bedrossian CW
    Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison.
    Bollinger DJ; Wick MR; Dehner LP; Mills SE; Swanson PE; Clarke RE
    Am J Surg Pathol; 1989 Aug; 13(8):659-70. PubMed ID: 2473660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas.
    Ordóñez NG
    Mod Pathol; 2013 Apr; 26(4):553-62. PubMed ID: 23196794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
    Ordóñez NG
    Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study.
    Zhou J; Iwasa Y; Konishi I; Kan N; Kannagi R; Kobashi Y; Kim YC; Yamabe H
    Cancer; 1995 Aug; 76(3):429-36. PubMed ID: 8625124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.